Decoy Therapeutics Inc.
DCOYAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2022 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-2.59| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-4.46 | $-2.88 | — | — |
| May 13, 2026 | $-4.18 | $-4.12 | — | — |
| Apr 3, 2026 | $-18.64 | $-6.48 | — | — |
| Nov 14, 2025 | $-1.81 | $-403.20 | — | — |
| Aug 11, 2025 | $-6.75 | $-396.00 | — | — |
| May 14, 2025 | $-15.44 | $-432.00 | — | — |
| Mar 21, 2025 | $-9.90 | $-415.80 | — | — |
| Nov 14, 2024 | $-11.39 | $-53.68 | — | — |
News
Lead pan-coronavirus program expected to file CTA/IND in 2H 2027 Optimized lead candidate shows potential for once-weekly dosing in preclinical studies Cash on balance sheet of $8.1 million at September 30, 2026 CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs) to target major respiratory and high-consequence viral threats, today provided a business update for the third quarter ende…
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York
Once-Weekly Intranasal Potential : Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue. Addressing Endemic Coronaviruses : DCOY-CoV is designed to protect against endemic human coronaviruses (OC43, 229E, NL63, HKU1, and SARS-CoV-2), in people at high risk of serious illness including the more than 20 million high-risk immunocompromised and 15 million COPD patients in the U.S. and Europe.
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction.
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the Series B Milestone Warrants to purchase shares of the Compan…
Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-…
Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Scienc…